HMGA1 and breast cancer: To this end, we treated two breast cancer cell models, one that overexpress HMGA1a and the other where the expression of HMGA1 has been silenced, with doxorubicin, a DSB inducer and one of the most effective agents for the treatment of breast cancer patients whose efficacy, however, is often compromised by resistance development [42, 43].